CN1562024A - Oral preparation containing ranolazine hydrochloride for treating cardiovascular disease - Google Patents
Oral preparation containing ranolazine hydrochloride for treating cardiovascular disease Download PDFInfo
- Publication number
- CN1562024A CN1562024A CN 200410012894 CN200410012894A CN1562024A CN 1562024 A CN1562024 A CN 1562024A CN 200410012894 CN200410012894 CN 200410012894 CN 200410012894 A CN200410012894 A CN 200410012894A CN 1562024 A CN1562024 A CN 1562024A
- Authority
- CN
- China
- Prior art keywords
- agent
- preparation
- ranolazine
- oral formulations
- lubricant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An orally-applied ranolazine hydrochloride for treating cardiovascular disease is prepared from ranolazine hydrochloride, diluent, adhesive, disintegrant, antisticking agent and lubricant through adding wetting agent, preparing soft material, granulating and drying.
Description
Technical field:
The present invention relates to treat the oral formulations and the preparation method of the hydrochloric ranolazine of cardiovascular disease.Taking said preparation makes the ranolazine in the human plasma maintain treatment level.
Background technology:
Ranolazine i.e. (±)-N-(2, the 6-3,5-dimethylphenyl) 4-[2-hydroxyl-3-(2-methoxyl group phenoxy group)-propyl group]-1-piperazine acetamide is that U.S. Pat 4567264 is open the earliest, it has illustrated that ranolazine and pharmaceutically acceptable salt thereof have superior medical functions, discloses it and has been used for the treatment of and comprises arrhythmia, variability and cardiovascular disease such as mobility's angina pectoris and myocardial infarction.
U.S. Pat 5506229 discloses ranolazine extremely is used for the treatment of the tissue that is subjected to physics and chemical damage at pharmaceutically acceptable salt purposes, comprise the anoxia or the reperfusion injury of cardioplegia, heart and skeletal muscle or cerebral tissue, also disclose the purposes that is used to transplant.Disclose conventional oral and parenteral formulation, comprised the sustained release preparation.Wherein this patent working example 7C and 7D have described the sustained release preparation of coated tablet and capsule form respectively, and the latter comprises the ranolazine microsphere and is coated with the microcrystalline Cellulose of sustained release polymer.
Chinese patent CN1045884C discloses the high dose oral preparation of ranolazine, said preparation be suitable for still for liquid contain effective dose be selected from RS-61443, Mycophenolic Acid and ranolazine filling solution as snap fit capsule or soft capsule.
Chinese patent CN1354665A discloses a kind of sustained release ranolazine formulations, the main component of said preparation makes the immixture and pH value dependency binding agent---the acrylic resin of ranolazine, its inhibition ranolazine discharges under one's belt, and promotes that ranolazine discharges in intestinal.Said preparation is suitable for one day 1～2 time, each 2; Show ranolazine hydrochloride 400mg in this patent working example 4, every day 3 times, treatment chronic stable angina pectoris is effectively, and human body tolerate the blood peak concentration of drug of said preparation, and its effect is more obvious behind raising dosage and the medicine frequency.This patent working example 5 healthy volunteer's single-dose results show the AUC of IR formulation
0～24(6530ng hour/ml) greater than the A (AUC that continues to discharge
0-245640ng hour/ml), B (AUC
0-245280ng hour/ml), C (AUC
0-245820ng hour/ml) preparation, show that the bioavailability of IR formulation is better than extended release preparation.The crude drug of this proprietary preparation is the ranolazine free alkali, and this patent fails to provide definite digital proof pH value dependency binding agent to promote the ranolazine free alkali to discharge in intestinal, and the AUC of its preparation
0～24Be significantly less than quick releasing formulation, prompting discharges probably and not exclusively causes absorption of human body incomplete.Because acrylic resin and ranolazine free alkali closely mix, the former is swellable in intestinal juice, and the ranolazine free alkali in intestinal juice slightly soluble to almost insoluble, thereby so this binding agent can stop the release fully of ranolazine free alkali to cause absorption of human body incomplete.
Therefore be necessary to prepare a kind of can discharge fully with give full play to ranolazine at the medicative preparation of human body planted agent.
Summary of the invention:
The invention provides a kind of oral formulations for the treatment of the hydrochloric ranolazine of cardiovascular disease, said preparation contains the ranolazine hydrochloride of 50～95wt%.Said preparation has good moistening, disintegrating property, can discharge medicine fast and fully, gives full play to the therapeutical effect of active component ranolazine.On the other hand, the present invention also provides the preparation method of the oral formulations of ranolazine hydrochloride, and said preparation is suitable for the patient to be taken 3～4 every day, and angina pectoris or other coronary artery disease are suffered from treatment by each 1～2 preparation unit.
The present invention includes the instructions of taking of the cardiovascular disease of said preparation treatment arrhythmia, variability and mobility's angina pectoris and myocardial infarction, contain the ranolazine hydrochloride amount in the preparation unit, so that the ranolazine level was kept 24 hours at least in the blood plasma, wherein this dosage is to divide to give for three times or four times in 24 hours.
" ranolazine hydrochloride " is chemical compound (±)-N-(2, the 6-3,5-dimethylphenyl)-4-[2-hydroxyl-3-(2-methoxyl group phenoxy group)-propyl group]-semihydrate of 1-piperazine acetamide dihydrochloride.Except as otherwise noted, the dihydrochloride that the weight of ranolazine hydrochloride and concentration are meant ranolazine among description of the present invention and the embodiment.
" extended release preparation ", be meant disclosed technology according to Chinese patent CN1354665A, promptly control the release of medicine by pH value dependency binding agent, make medicine in about 6 hours or longer time in the harmonization of the stomach intestinal preparation of slow and continuous-dissolution and absorption.
" oral formulations " is meant that disintegrate is complete in gastrointestinal, and the preparation of release of active ingredients, said preparation are suitable for the patient to be taken 3～4 times easily every day, and should there be therapeutical effect in each 1～2 preparation unit so that active component is brought into play it in patient's body.
" transformation ratio ", be meant the transforming relationship of ranolazine hydrochloride and ranolazine free alkali, when representing dosage with alkali and dihydrochloride dual mode, the transformation ratio that dihydrochloride is converted into alkali is 0.854, and the meaning of expression is that the ranolazine hydrochloride of 1g (molecular weight 500.53) is equivalent to 0.854g ranolazine free alkali (molecular weight 427.54).
Ranolazine hydrochloride oral formulations of the present invention, it comprises the immixture of the definite shape that ranolazine hydrochloride and suitable medicinal inert excipient make, as compressed tablet or granule, also can be in the outer gastric solubility coatings that covers of immixture with the outward appearance of improving preparation and stability etc., ranolazine hydrochloride oral formulations of the present invention, be meant ranolazine hydrochloride in simulated gastric fluid in (common in vitro tests is the hydrochloric acid solution of preparation at 0.1mol/L) 45 minutes disintegrate discharge and be no less than 70%, promptly show to discharge fully.Table 1 has been summarized the solubility property (with reference to Chinese Pharmacopoeia 2000 year version) of ranolazine hydrochloride under different pH value
The solubility property of table 1 ranolazine hydrochloride under different pH value
| PH value | ??1.0 | ??3.0 | ??5.0 | ??6.5 | ??7.0 | ??7.5 | ??8.0 | ??8.5 |
| Dissolubility | Yi Rong | Yi Rong | Yi Rong | Yi Rong | Yi Rong | Dissolving | Dissolving | Dissolving |
Wherein easily moltenly show the dissolving fully in 10～30ml solvent of 1g solute, dissolving shows the dissolving fully in 30～100ml solvent of 1g solute.
For ranolazine hydrochloride disintegrate in human body is discharged fully, be necessary to select one or more inert excipients.This excipient can guarantee that the ranolazine hydrochloride disintegrate discharges fully, can meet China's industrialized great production reality again, and production technology is simple.If the ranolazine hydrochloride preparation is stripping and being absorbed fully in human body, make that the ranolazine hydrochloride concentration difference is very big in the individual blood plasma, be not easy to treatment, and unforeseeable untoward reaction might take place.
Therefore the oral formulations of treatment cardiovascular disease of the present invention comprises hydrochloric acid Reynolds and one or more pharmaceutically acceptable inert excipients of 50wt% at least, and described oral formulations comprises tablet, granule, capsule; Described inert excipient comprises diluent, binding agent, disintegrating agent, antitack agent and lubricant; Described diluent be selected from microcrystalline Cellulose, lactose, starch and pregelatinized Starch, and composition thereof; Described binding agent be selected from sodium alginate, sodium carboxymethyl cellulose, hyetellose, hyprolose, hydroxypropyl emthylcellulose, methylcellulose, gelatin, polyvinylpyrrolidone, cellulose acetate, starch, pregelatinized Starch, and composition thereof; Described disintegrating agent be selected from alginic acid, sodium alginate, sodium carboxymethyl cellulose, microcrystalline Cellulose, cellulose powder, cross-linking sodium carboxymethyl cellulose, crospolyvinylpyrrolidone, pregelatinized Starch, starch, and composition thereof; Described antitack agent be selected from micropowder silica gel, silicon dioxide, magnesium trisilicate and Pulvis Talci, and composition thereof; Described lubricant be selected from magnesium stearate, Pulvis Talci, and composition thereof, used wetting agent is an ethanol water.
Contain in the oral formulations of the present invention: the ranolazine hydrochloride of 50～95wt%, the diluent of 1～45wt%, the binding agent of 2～20wt%, the disintegrating agent of 1～10wt%, the antitack agent of 0.1～5wt%, the lubricant of 0.2～5wt%.
Oral formulations preferred ingredient of the present invention is formed: the ranolazine hydrochloride of 55～90wt%, the diluent of 2～40wt%, the binding agent of 5～15wt%, the disintegrating agent of 2～8wt%, the antitack agent of 0.2～4.0wt%, the lubricant of 0.5～2.0wt%.
The ranolazine hydrochloride of 200～500mg is contained in the preparation unit of oral formulations of the present invention, is suitable for the patient and takes every day 3～4 times, each 1～2 preparation unit.
Preferable absorbent is a microcrystalline Cellulose in the oral formulations of the present invention; Binding agent is pregelatinized Starch; Disintegrating agent is a cross-linking sodium carboxymethyl cellulose; Antitack agent is micropowder silica gel; Lubricant is a magnesium stearate.
Also can be in outer outward appearance, the sense of taste and the stability etc. of gastric solubility coatings that cover of preparation of the present invention to improve preparation, the coating weightening finish is 0.1～20% with the weight ratio of compressed tablet, and is preferred 0.5～18%, the best is 1.0～15%.
Particularly preferred oral formulations of the present invention is made up of following component:
| Component | Weight range (%) | Preferred weight range (%) |
| Ranolazine hydrochloride | ????50～95 | ??55～90 |
| Pregelatinized Starch | ????2～20 | ??5～15 |
| Microcrystalline Cellulose | ????1～45 | ??2～25 |
| Cross-linking sodium carboxymethyl cellulose | ????1～10 | ??2～8 |
| Micropowder silica gel | ????0.1～5 | ??0.2～4.0 |
| Magnesium stearate | ????0.2～5 | ??0.5～2.0 |
| Ethanol water | To wetting amount | To wetting amount |
Wherein concentration of ethanol is 5～95wt% in the ethanol water, preferred 20～75wt%.
The oral formulations of treatment cardiovascular disease of the present invention prepares as follows:
1) compressed tablet: ranolazine hydrochloride and selectable diluent and Nei Jia disintegrating agent are put in the mixer; add an amount of wetting agent or binding agent and make soft material; soft material pressed suitable screen cloth wet granular; it is dry immediately; granulate sieves; to add the dried granule mix homogeneously of disintegrating agent and selectable lubricant and gained, tabletting promptly gets label.Circular plate shape of the present invention.Preferred method of granulating is to stir to granulate or the boiling granulating after drying.
2) gelatin hard wafer: with ranolazine hydrochloride and the even dry mixture that gets of selectable mixed with excipients, the employing wet granulation process is granulated, with wet grain drying, the granulate that sieves, with selectable lubricant (as magnesium stearate) and other auxiliary agent mix homogeneously, in the snap fit capsule of packing into.
3) granule: ranolazine hydrochloride and selectable excipient and correctives mix homogeneously are got dry mixture, adopt wet granulation process to granulate,, be divided in the medicinal aluminum-plastic composite membrane bag with wet grain drying, the granulate that sieves.
The advantage of above-mentioned preparation method is: the binding agent of use is an ethanol water, and consumption is few, and preparation technology is simple, is suitable for domestic production technology and equipment condition.
The present invention also has an advantage to be: adopt ranolazine dihydrochloride rather than the ranolazine free alkali crude drug as ranolazine hydrochloride oral formulations of the present invention, because the dissolubility of ranolazine hydrochloride does not have greatly changed with pH, the absorption so this preparation both can dissolve in the stomach, also can in intestinal, absorb, like this, make medicine absorb more fully, can reduce that preparation absorbs and the individual variation of curative effect in patient's body.Simultaneously, when medicine frequency increased to 3～4 times, the dosage of at every turn taking medicine had reduced, so the size shape of preparation needing to be more suitable for the patient crowd of ranolazine treatment.Because this crowd is older, preparation is too big or shape is not good, then is unfavorable for swallowing.
The oral formulations of the hydrochloric ranolazine of treatment cardiovascular disease of the present invention provides following treatment advantage:
This preparation is raw material with the ranolazine hydrochloride, and its dissolubility does not have greatly changed with the variation of pH value, and drug release gets more complete, reduces farthest that preparation absorbs in patient's body and the individual variation of curative effect.Because the increase of medicining times, the preparation size shape is more suitable for the medication crowd and takes.
In addition, preparation technology of the present invention is simple, meets domestic production technology and equipment condition.
Therefore the present invention is favourable for enterprise and patient.
The specific embodiment:
Providing the following example makes person skilled in art's clearer understanding of energy and implements the present invention.They should not be counted as limiting the scope of the invention, and only are illustrative and representational example.
Embodiment 1
The composition and the preparation method of 200mg ranolazine hydrochloride compressed tablet
With ranolazine hydrochloride 200.0g, microcrystalline Cellulose 100.0g, calcium hydrogen phosphate 40.0g, micropowder silica gel 40.0g mix homogeneously, with the 40wt% ethanol water is wetting agent system soft material, 20 mesh sieves are granulated, 60 ℃ of aeration-drying 4 hours, granulate, add sodium carboxymethyl cellulose 5.0g, magnesium stearate 5.0g mixing press about 1000 round, every hydrochloric ranolazine 200mg promptly gets compressed tablet.
Embodiment 2
The composition and the preparation method of 300mg ranolazine hydrochloride compressed tablet
With ranolazine hydrochloride 300.0g, microcrystalline Cellulose 100.0g, calcium hydrogen phosphate 30.0g, micropowder silica gel 30.0g mix homogeneously, with the 60wt% ethanol water that contains the 5wt% polyvinylpyrrolidone is wetting agent system soft material, 20 mesh sieves are granulated, 60 ℃ of aeration-drying 3 hours, granulate, add micropowder silica gel 15.0g, magnesium stearate 5.0g mixing press about 1000 capsule matrix, every hydrochloric ranolazine 300mg promptly gets compressed tablet.
Embodiment 3
The composition and the preparation method of 500mg ranolazine hydrochloride compressed tablet
With ranolazine hydrochloride 500.0g, microcrystalline Cellulose 60.0g, calcium hydrogen phosphate 50.0g, micropowder silica gel 40.0g mix homogeneously, with the 70wt% ethanol water is wetting agent system soft material, 20 mesh sieves are granulated, 60 ℃ of aeration-drying 3 hours, granulate, add micropowder silica gel 10.0g, polyvinylpyrrolidone 15.0g, magnesium stearate 5.0g mixing press the capsule matrix, every hydrochloric ranolazine 500mg promptly gets compressed tablet.
Embodiment 4
Capsular composition of 200mg ranolazine hydrochloride and preparation method
Ranolazine hydrochloride 200.0g, microcrystalline Cellulose 50.0g and calcium hydrogen phosphate 40.0g are inserted in quick mixer granulator KJZ～10; spraying the 30wt% ethanol water granulates; 60 ℃ of aeration-drying 3 hours; 40 mesh sieve granulate; add magnesium stearate 10.0g mixing; No. 1 snap fit capsule of fill makes the hydrochloric ranolazine 200mg of every capsules.
Embodiment 5
Particulate composition of 400mg ranolazine hydrochloride and preparation method
With ranolazine hydrochloride 400.0g, methylcellulose 50.0g, microcrystalline Cellulose 100.0g, gelatin 10.0g, aspartame 0.05g and partially pregelatinized starch 20.0g mixing, spray the polyvinylpyrrolidone ethanol water system soft material of 3wt%, granulate, dry 2 hours of convection oven, 18 mesh sieve granulate, be divided in the PVC clad aluminum foil bag, make every bag of hydrochloric ranolazine 400mg.
Embodiment 6
The composition and the preparation method of 300mg ranolazine hydrochloride Film coated tablets
With ranolazine hydrochloride 300.0g, microcrystalline Cellulose 100.0g, calcium hydrogen phosphate 30.0g, micropowder silica gel 30.0g mix homogeneously, with the 60wt% ethanol water that contains 5% polyvinylpyrrolidone is wetting agent system soft material, 20 mesh sieves are granulated, 60 ℃ of aeration-drying 3 hours, granulate adds micropowder silica gel 15.0g, magnesium stearate 5.0g mixing tabletting, compressed tablet bag OPADRY film, promptly get every hydrochloric ranolazine 300mg, Film coated tablets.
Embodiment 7
The composition and the preparation method of 300mg ranolazine hydrochloride compressed tablet
With ranolazine hydrochloride 300.0g, microcrystalline Cellulose 80.0g, calcium hydrogen phosphate 50.0g, micropowder silica gel 40.0g, micropowder silica gel 10.0g, polyvinylpyrrolidone 10.0g, magnesium stearate 2.0g mix homogeneously, adopt rolling process to be pressed into sheet, sheet is broken, sieve to such an extent that dried particles is used in compacting with 18 orders and 40 mesh sieves, add polyvinylpyrrolidone 5.0g, magnesium stearate 3.0g mixing tabletting, must about 1000 compressed tablets, every hydrochloric ranolazine 300mg.
Embodiment 8
The not coated preparation that external comparing embodiment 1～4 makes.
Present embodiment describe in detail not coated preparation that the embodiment of the invention 1～4 makes according in " Chinese Pharmacopoeia version in 2000 " two appendix about the accordingly result of disintegration and dissolution determination method test.
Disintegration: 6 of sample thiefs or, place the glass tubing of hanging basket respectively, start disintegration tester and check.
Dissolution: use 900ml0.1mol/L hydrochloric acid as dissolution medium, 37 ℃ of temperature adopt Chinese Pharmacopoeia appendix dissolution method first subtraction unit, 100 rev/mins of rotating speeds, and sampling 10ml measures after 30 minutes.Table 3 has been summed up the dissolution data of the embodiment of the invention 1～4 prepared ranolazine hydrochloride preparation.
Table 2. embodiment 1～4 external stripping contrast
| Embodiment | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 |
| Disintegration (minute) | ???10 | ???7.0 | ????6.0 | ???12.0 |
| Stripping percentage ratio (%) | ???96.4 | ???97.1 | ????97.8 | ???98.2 |
Last watch test data show, meet the regulation of Chinese Pharmacopoeia 2000 year version all less than 15 minutes the disintegration of the embodiment 1～4 that implements by the technology of the present invention, and promptly the technology of the present invention is feasible, basic release fully in 45 minutes in acid, i.e. release is no less than 70%.
Claims (5)
1. oral formulations for the treatment of cardiovascular disease is characterized in that: said preparation comprises hydrochloric acid Reynolds and one or more pharmaceutically acceptable inert excipients of 50wt% at least, and described oral formulations comprises tablet, granule, capsule; Described inert excipient comprises diluent, binding agent, disintegrating agent, antitack agent and lubricant; Described diluent be selected from microcrystalline Cellulose, lactose, starch and pregelatinized Starch, and composition thereof; Described binding agent be selected from sodium alginate, sodium carboxymethyl cellulose, hyetellose, hyprolose, hydroxypropyl emthylcellulose, methylcellulose, gelatin, polyvinylpyrrolidone, cellulose acetate, starch, pregelatinized Starch, and composition thereof; Described disintegrating agent be selected from alginic acid, sodium alginate, sodium carboxymethyl cellulose, microcrystalline Cellulose, cellulose powder, cross-linking sodium carboxymethyl cellulose, crospolyvinylpyrrolidone, pregelatinized Starch, starch, and composition thereof; Described antitack agent be selected from micropowder silica gel, silicon dioxide, magnesium trisilicate and Pulvis Talci, and composition thereof; Described lubricant be selected from magnesium stearate, Pulvis Talci, and composition thereof, used wetting agent is an ethanol water.
2. oral formulations as claimed in claim 1 is characterized in that containing in the preparation: the ranolazine hydrochloride of 50～95wt%, the diluent of 1～45wt%, the binding agent of 2～20wt%, the disintegrating agent of 1～10wt%, the antitack agent of 0.1～5wt%, the lubricant of 0.2～5wt%.
3. oral formulations as claimed in claim 1 is characterized in that containing in the preparation: the ranolazine hydrochloride of 55～90wt%, the diluent of 2～40wt%, the binding agent of 5～15wt%, the disintegrating agent of 2～8wt%, the antitack agent of 0.2～4.0wt%, the lubricant of 0.5～2.0wt%.
4. as the described oral formulations of claim 1-3, it is characterized in that said preparation unit contains the ranolazine hydrochloride of 200～500mg, be suitable for the patient and take every day 3～4 times, each 1～2 preparation unit.
5. oral formulations as claimed in claim 1 is characterized in that its diluent is a microcrystalline Cellulose; Binding agent is pregelatinized Starch; Disintegrating agent is a cross-linking sodium carboxymethyl cellulose; Antitack agent is micropowder silica gel; Lubricant is a magnesium stearate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410012894 CN1248690C (en) | 2004-03-25 | 2004-03-25 | Oral preparation containing ranolazine hydrochloride for treating cardiovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410012894 CN1248690C (en) | 2004-03-25 | 2004-03-25 | Oral preparation containing ranolazine hydrochloride for treating cardiovascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1562024A true CN1562024A (en) | 2005-01-12 |
| CN1248690C CN1248690C (en) | 2006-04-05 |
Family
ID=34478043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410012894 Expired - Fee Related CN1248690C (en) | 2004-03-25 | 2004-03-25 | Oral preparation containing ranolazine hydrochloride for treating cardiovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1248690C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100427076C (en) * | 2005-11-10 | 2008-10-22 | 贵州益佰制药股份有限公司 | Medicinal preparation for treating embolus and its preparation method |
| CN100455288C (en) * | 2006-06-26 | 2009-01-28 | 哈药集团制药总厂 | Formula of Reynoldazine hydrochloride prepn. |
| CN111000818A (en) * | 2020-01-04 | 2020-04-14 | 东莞市东阳光仿制药研发有限公司 | Ranolazine composition and preparation method thereof |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
| SG11201407300VA (en) | 2012-05-07 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of neurological disorders |
| US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
| US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
| WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
| WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
| WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
| US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
| US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
| WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
| WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
| US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
| US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
| WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
| US9765020B2 (en) | 2012-05-23 | 2017-09-19 | Cellix Bio Private Limited | Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis |
| CN104603100A (en) | 2012-05-23 | 2015-05-06 | 塞利克斯比奥私人有限公司 | Compositions and methods for treatment of inflammatory bowel disease |
| JP2015518854A (en) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | Compositions and methods for the treatment of multiple sclerosis |
| WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
| WO2014027262A2 (en) * | 2012-08-14 | 2014-02-20 | Mahesh Kandula | Compositions and methods for the treatment angina and cardiovascular conditions |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| CA2914461A1 (en) | 2013-06-04 | 2014-12-11 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| WO2016046835A1 (en) | 2014-09-26 | 2016-03-31 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| CA2967908C (en) | 2014-09-29 | 2020-11-17 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
| EP3212626B1 (en) | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| SG11201705524SA (en) | 2015-01-06 | 2017-08-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of inflammation and pain |
-
2004
- 2004-03-25 CN CN 200410012894 patent/CN1248690C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100427076C (en) * | 2005-11-10 | 2008-10-22 | 贵州益佰制药股份有限公司 | Medicinal preparation for treating embolus and its preparation method |
| CN100455288C (en) * | 2006-06-26 | 2009-01-28 | 哈药集团制药总厂 | Formula of Reynoldazine hydrochloride prepn. |
| CN111000818A (en) * | 2020-01-04 | 2020-04-14 | 东莞市东阳光仿制药研发有限公司 | Ranolazine composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1248690C (en) | 2006-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1248690C (en) | Oral preparation containing ranolazine hydrochloride for treating cardiovascular disease | |
| CN1146427C (en) | Solid oral dosage form comprising combination of metformin and glibenclamide | |
| CN102764264A (en) | Celecoxib solid composition with high dissolution, preparation method and application | |
| CN102600132A (en) | Oral preparation containing amisulpride | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| WO2003039527A1 (en) | Controlled release tablets of metformin | |
| KR20050053648A (en) | Novel pharmaceutical formulations of modafinil | |
| CN1943586A (en) | Oral disintegrating tablet using roxithromycin and ambroxol hydrochloride as active component and its preparing method and use | |
| RU2326660C1 (en) | Oral pharmaceutical composition memantin (options) and method of preparation (options) | |
| CN1903183A (en) | Dispersion tablets of telbivudine and its prepn. method | |
| CN106138059A (en) | A kind of stable Li Gelieting pharmaceutical composition | |
| CN109464442B (en) | Sacubitril valsartan sodium pharmaceutical composition and preparation method thereof | |
| CN101647781B (en) | Preparation method of ligustrazine phosphate powder injection | |
| CN106511291A (en) | Acotiamide hydrochloride controlled release tablet and preparation method thereof | |
| CN109125270B (en) | Solid preparation and preparation method thereof | |
| CN115813874A (en) | Preparation method of oral three-part combined hypoglycemic double-release tablet and preparation thereof | |
| CN1058715A (en) | Ifosfamide is the solid orally ingestible of active component | |
| CN1853634A (en) | Composition comprising itraconazole for oral administration | |
| CN105407876A (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
| CN102198138B (en) | Compound antitubercular preparation containing gatifloxacin, and preparation method thereof | |
| CN108938580B (en) | Paroxetine hydrochloride oral disintegrating tablet | |
| CN110833530A (en) | Dapoxetine hydrochloride orally disintegrating tablet and preparation method and application thereof | |
| CN105012247A (en) | Diacerein composition and preparation method thereof | |
| CN100364519C (en) | Chewing tablet of tramado hydrochloride and its preparation method | |
| CN1254240C (en) | Silibinin meglumine salt oral disintegration tablet preparation and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060405 Termination date: 20100325 |